Robin Carhart-Harris Ph.D.
Robin Carhart-Harris moved to Imperial College London in 2008 after obtaining a PhD in Psychopharmacology from the University of Bristol, focused on the serotonin system, and an MA in Psychoanalysis from Brunel University, 2005. Robin has designed human brain imaging studies with LSD, psilocybin, MDMA and DMT, a clinical trial of psilocybin for treatment-resistant depression, a double-blind randomized controlled trial comparing psilocybin with the SSRI, escitalopram, for depression, published in the New England Journal of Medicine, and a multimodal imaging study in first time users of psilocybin. Robin has published over 105 scientific papers. He founded the Centre for Psychedelic Research at Imperial College London in April 2019, the first of its kind in the world. In 2021, he was listed in TIME magazine’s ‘100 Next’, a list of 100 rising stars shaping the future. From July 1st 2021, he will move to University of California, San Francisco, becoming the Ralph Metzner Distinguished Professor in Neurology and Psychiatry. At UCSF, Robin will serve as Director of the new Psychedelics Division within the translational neuroscience Centre, Neuroscape.
Head of Centre for Psychedelic Research
Imperial College London
Matthew W. Johnson Ph.D.
Matthew W. Johnson, Ph.D., is The Susan Hill Ward Endowed Professor of Psychedelics and Consciousness Research at Johns Hopkins. Working with psychedelics for 17 years, he is one of the world’s most widely published experts on psychedelics. Matt published psychedelic safety guidelines in 2008, helping to resurrect psychedelic research. He developed the first research on psychedelic treatment of tobacco addiction and published initial results in 2014, and with colleagues he conducted the largest study of psilocybin in cancer distress (2016). His 2018 psilocybin review recommended Schedule IV upon medical approval. Matt also conducts behavioral economic research on addiction and sexual risk. He’s been Interviewed by Anderson Cooper on 60 Minutes, the New York Times, the Washington Post, the Wall Street Journal, the BBC and was featured in Michael Pollan’s book How to Change Your Mind.
Professor of Psychiatry and Behavioral Sciences
Johns Hopkins University School of Medicine
Rachel Yehuda Ph.D.
Rachel Yehuda, Ph.D. is the Director of the Center for the Study of Psychedelic Psychotherapy and Trauma, Director for the Traumatic Stress Studies Division, Vice Chair for Veterans Affairs for the Psychiatry Department and a Professor of Psychiatry and Neuroscience at the Icahn School of Medicine at Mount Sinai. She is also the Director of Mental Health at the Bronx Veterans Affairs Medical Center. Throughout her career her research has focused on the study of the enduring effects of trauma exposure, particularly PTSD, as well as associations between biological and psychological measures. In 1992 she founded the Specialized Clinical Program for Holocaust Survivors and their families, and spearheaded work on intergenerational trauma and epigenetic transmission. In addition to her scientific accomplishments in the area of trauma and PTSD, Dr. Yehuda teaches pastoral counseling at the Yeshivat Chovevei Torah Rabbinical School, and co-authored a volume entitled “A Guide to Jewish Pastoral Counseling” with Dr. Michelle Friedman.
Director of the Center for Psychedelic Psychotherapy and Trauma Research
Ben Lightburn is a proven entrepreneur and leader specializing in the research, development and commercialization of novel extraction technologies. Ben’s expertise in these areas led him to found Filament Health, an exclusively natural psychedelic drug discovery and extraction technology company.
CEO and Co-Founder
Bruce has a passion for entrepreneurship and making a positive difference in the world. He brings a wealth of experience in building strong technology driven companies, developing world-class teams, and positioning his companies in sectors driven by waves of public policy change. Mr. Linton is Founder and served as the Chairman and Chief Executive Officer of Canopy Growth Corporation (Nasdaq: CGC/TMX:WEED). As Chairman and Chief Executive Officer of Canopy Growth Corporation, Mr. Linton led the Company through over 16 rounds of financing, 31 acquisitions and $6 billion of capital raises, including a $5 billion investment by Constellation Brands, the largest beer import company in the United States. In September 2019 Mr. Linton joined as Executive Chairman of Gage Growth Corp. (CSE:GAGE), a Michigan-based vertically integrated cannabis company, and as a director of Mind Medicine Inc.(NEO:MMED), a psychedelic medicine biotech company, and has also served as Co-Chairman of Martello Technologies Group (TSX-V:MTLO), a user experience focused cloud computing collaboration company since 2018. Co-founder, Chairman and acting CEO of Ruckify, a peer-to-peer marketplace. Chairman of the Advisory Board for Red Light Holland Corp. is co-founder and Non-Executive Chairman of Óskare Capital, on the Board of the Canadian Olympic Foundation.
Chair of Advisory Board with Red Light Holland Corp and Board Member with Mind Medicine Inc.
David Nichols Ph.D.
David E. Nichols, PhD is currently an Adjunct Professor in the Eshelman School of Pharmacy at the University of North Carolina, Chapel Hill, NC. He is a Distinguished Professor Emeritus at the Purdue University College of Pharmacy and was the Robert C. and Charlotte P. Anderson Distinguished Chair in Pharmacology, where he carried out teaching and research for 38 years prior to his retirement in 2012. In 2004 he was named the Irvine H. Page Lecturer by the International Society for Serotonin Research, he received the first Purdue Provost’s Outstanding Graduate Mentor award in 2006, and was named a Distinguished Alumnus by the University of Iowa College of Pharmacy in 2012. He began studying psychedelics in 1969 while a graduate student and continued that research throughout his entire professional career, being one of only a few investigators able to research psychedelics after they were scheduled. In 1993 he founded the Heffter Research Institute (HRI), which funded the first rigorous clinical studies of psychedelics in humans after a nearly 40-year moratorium and served as its president for more than 25 years. HRI funded the groundbreaking Phase I and II studies of psilocybin for the treatment of depression, as well as substance use disorders. Dr. Nichols also synthesized the DMT used by Dr. Rick Strassman in his human studies, the MDMA that MAPS used for their Phase I and II clinical trials for PTSD, and the psilocybin used by several investigators for human clinical studies including the Phase I and II trials conducted at Johns Hopkins University by Roland Griffiths and his colleagues. He is considered the world’s leading expert on the chemistry of psychedelics. Dr. Nichols, although officially retired, remains active in the field through consulting and collaborations with several academic and pharmaceutical organizations and continues to publish scientific papers.
Purdue University College of Pharmacy
Rick Doblin Ph.D.
Founder Rick Doblin, Ph.D., is the founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS). He received his doctorate in Public Policy from Harvard’s Kennedy School of Government, where he wrote his dissertation on the regulation of the medical uses of psychedelics and marijuana and his Master’s thesis on a survey of oncologists about smoked marijuana vs. the oral THC pill in nausea control for cancer patients. His undergraduate thesis at New College of Florida was a 25-year follow-up to the classic Good Friday Experiment, which evaluated the potential of psychedelic drugs to catalyze religious experiences. He also conducted a thirty-four year follow-up study to Timothy Leary’s Concord Prison Experiment. Rick studied with Dr. Stanislav Grof and was among the first to be certified as a Holotropic Breathwork practitioner. His professional goal is to help develop legal contexts for the beneficial uses of psychedelics and marijuana, primarily as prescription medicines but also for personal growth for otherwise healthy people, and eventually to become a legally licensed psychedelic therapist. He founded MAPS in 1986, and currently resides in Boston with his wife, dog, and empty rooms from three children, one of whom is in college and two have graduated.